UMIN-ICDS Clinical Trial

Unique ID issued by UMIN UMIN000063519
Receipt number R000072696
Scientific Title A prospective IVI validation of coronary stent optimization after CT-guided PCI
Date of disclosure of the study information 2026/11/05
Last modified on 2026/11/05 07:30:03

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A prospective IVI validation of coronary stent optimization after CT-guided PCI

Acronym

The ACTION-CT PCI Study

Scientific Title

A prospective IVI validation of coronary stent optimization after CT-guided PCI

Scientific Title:Acronym

A prospective IVI validation of coronary stent optimization after CT-guided PCI

Region

Japan


Condition

Condition

Stable angina pectoris

Classification by specialty

Cardiology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

The aim of this study is to prospectively evaluate the frequency of intravascular imaging findings that may warrant additional stent optimization following CT-guided PCI. This study is designed as a mechanistic investigation to objectively assess post-PCI findings after CT-guided PCI, rather than to compare clinical outcomes or evaluate treatment efficacy.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Primary Outcome

The proportion of patients with at least one intravascular imaging finding that may warrant additional stent optimization, as identified by post hoc analysis following CT-guided PCI.

IVUS Criteria for Findings Potentially Requiring Additional Optimization

Stent underexpansion: Minimum stent area (MSA) of 5.0 mm2 or less, or less than 90% of the distal reference lumen area.

Significant residual plaque burden: Plaque burden of 50% or greater within 5 mm proximal or distal to the stent edge.

Significant stent edge dissection: Dissection involving the media or measuring 3 mm or greater in length.

OCT Criteria for Findings Potentially Requiring Additional Optimization

Suboptimal stent expansion: Failure to meet all of the following criteria:

MSA of at least 80% of the mean reference lumen area.

MSA of at least 100% of the distal reference lumen area.

MSA greater than 4.5 mm2.

Suboptimal stent apposition: Maximum malapposition distance of 400 um or greater.

Major stent edge dissection: Presence of any of the following:

Dissection flap angle of 60 degrees or greater.

Dissection length of 3 mm or greater.

Deep vessel injury involving the media or deeper vessel layers.

These criteria are based on previous studies and established clinical considerations and do not represent study-specific criteria mandating additional intervention.

Key secondary outcomes



Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

18 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1.Patients who have undergone preprocedural coronary computed tomography angiography (CCTA).

2.Patients with clinically suspected myocardial ischemia who are scheduled for elective percutaneous coronary intervention (PCI). The indication for revascularization is determined based on coronary angiography, invasive FFR, FFRCT, myocardial perfusion imaging, or exercise electrocardiography, in accordance with the Japanese Circulation Society (JCS) guidelines.

3.Patients with non-culprit lesions following acute coronary syndrome (ACS) are also eligible.

4.Patients in whom intravascular ultrasound (IVUS) or optical coherence tomography (OCT) assessment is feasible during PCI.

5.Patients who have provided written informed consent to participate in the study.

Key exclusion criteria

1.Patients requiring emergency PCI.

2.Patients with in-stent restenosis.

3.Patients with left main coronary artery disease, chronic total occlusion, complex bifurcation lesions, or severely calcified lesions.

4.Patients with three-vessel disease for whom surgical revascularization is considered more appropriate.

5.Patients unable to continue antiplatelet or anticoagulant therapy.

6.Patients considered unsuitable for study participation due to active malignancy or other conditions.

7.Patients in whom preprocedural CCTA analysis is not feasible due to poor image quality or other technical limitations.

8.Patients with severe renal dysfunction for whom contrast administration is considered clinically inappropriate (e.g., eGFR less than 30 mL/min/1.73 m2). Patients receiving maintenance dialysis are eligible.

9.Patients in whom CCTA or PCI cannot be safely performed due to contrast media allergy or other contraindications.

10.Patients with severe systemic conditions that make study participation inappropriate, including severe heart failure, active infection, or diseases associated with a limited life expectancy.

11.Patients who are unlikely to comply with the study procedures, including those for whom continued follow-up after informed consent is difficult.

12.Patients considered unsuitable for study participation for any other reason, as determined by the principal investigator or treating physician.

Target sample size

100


Research contact person

Name of lead principal investigator

1st name Tajima
Middle name
Last name Atomu

Organization

Aichi medical university hospital

Division name

Department of Cardiology

Zip code

440-0814

Address

1-1 Yazakokarimata, Nagakute, Aichi,Japan

TEL

09091967254

Email

atomu.tajima0118@outlook.jp


Public contact

Name of contact person

1st name Atomu
Middle name
Last name Tajima

Organization

Aichi Medical University Hospital

Division name

Department of Cardiology

Zip code

480-1195

Address

1-1 Yazakokarimata, Nagakute, Aichi,Japan

TEL

0561-62-3311

Homepage URL


Email

atomu.tajima0118@outlook.jp


Sponsor or person

Institute

Aichi Medical University

Institute

Department

Personal name



Funding Source

Organization

Aichi Medical University

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Ethics Committee of Aichi Medical University School of Medicine

Address

1-1 Yazakokarimata, Nagakute, Aichi,Japan

Tel

0561-62-3311

Email

amu_ethics@aichi-med-u.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2026 Year 11 Month 05 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Open public recruiting

Date of protocol fixation

2026 Year 03 Month 16 Day

Date of IRB

2026 Year 03 Month 16 Day

Anticipated trial start date

2026 Year 04 Month 24 Day

Last follow-up date

2027 Year 12 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

This is an observational study evaluating stent implantation results using intravascular imaging (IVUS/OCT) following CT-guided PCI. Intravascular imaging findings, including stent expansion, malapposition, edge dissection, and residual plaque, will be assessed to determine the frequency of findings warranting consideration of additional optimization. The decision to perform additional treatment will be left to the operator's discretion.


Management information

Registered date

2026 Year 11 Month 05 Day

Last modified on

2026 Year 11 Month 05 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000072696